Navigation Links
BioSpecifics Technologies Corp. Reports First Quarter 2009 Financial Results
Date:5/11/2009

xpenses were primarily due to higher stock-based compensation expense and outside consulting expense partially offset by lower legal fees.

As of March 31, 2009, BioSpecifics held cash, cash equivalents and short-term investments of $10.7 million, compared to $4.4 million as of December 31, 2008.

First Quarter and Recent Corporate Highlights

  • BioSpecifics' common stock began trading on the Nasdaq Global Market under the ticker BSTC on January 9, 2009.

  • On February 2, 2009, Auxilium announced the completion of enrollment in a randomized, double-blind, placebo-controlled U.S. Phase IIb clinical trial for XIAFLEX(TM) for Peyronie's disease. Over 120 patients were enrolled, and all dosing was completed on April 30, 2009. Top-line results from the study are expected to be reported in the fourth quarter of 2009.

  • On February 3, 2009, BioSpecifics announced that it received an upfront sublicense payment of $6.375 million on January 30, 2009 from Auxilium as a result of its partnership agreement with Pfizer to market XIAFLEX(TM) in 48 countries including Europe.

  • On April 28, 2009, the FDA accepted for Priority Review Auxilium's BLA for XIAFLEX(TM) for the treatment of Dupuytren's disease. Auxilium filed the BLA on February 27, 2009 and included data from 1,082 subjects and over 2,600 injections. The Prescription Drug User Fee Act (PDUFA) date has been set for August 28, 2009. If approved by the FDA, Auxilium plans to launch in the U.S. within 60 days, which would be the end of the calendar year.

About BioSpecifics Technologies Corp.

BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable co
'/>"/>

SOURCE BioSpecifics Technologies Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. BioSpecifics Technologies Corp. Announces FDA Acceptance of Biologics License Application With Priority Review for XIAFLEX(TM) for the Treatment of Dupuytrens Disease
2. BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2008 Financial Results
3. BioSpecifics Technologies Corp. Announces Listing on NASDAQ Global Market
4. BioSpecifics Technologies Corp. to Present at Piper Jaffray 20th Annual Health Care Conference
5. BioSpecifics Technologies Corp. Announces Appointment of Dr. Matthew Geller to Board of Directors
6. BioSpecifics Technologies Corp. Buys Down Royalties for Peyronies Disease
7. BioSpecifics Technologies Corp. Reports Second Quarter 2008 Financial Results
8. BioSpecifics Technologies Corp. Announces Additional Sales of Stock in Private Placement Offering
9. BioSpecifics Technologies Corp. Announces Sale of Stock in Private Placement Offering
10. BioSpecifics Technologies Corp. Announces Repayment of Outstanding Loan
11. BioSpecifics Technologies Corp. Announces Sale of Stock in Private Placement Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 2015  Discovery Laboratories, Inc. (Nasdaq: DSCO ... second $1.0M tranche under a previously awarded Phase ... at up to $3.0 million to support continued ... a potential medical countermeasure to mitigate acute and ... an initial $1.0 million under this grant in ...
(Date:7/29/2015)... PARIS , July 30, 2015 ... de la santé, publie ses résultats pour le ... Brandicourt commente les résultats. Visionner ... http://www.eurobusinessmedia.com/ceo-direct/sanofi/sanofi-h1-2015-results-interview-with-ceo-olivier-brandicourt?utm_source=ceo-direct&utm_medium=wire Au sommaire ... - Moteurs de croissance ...
(Date:7/29/2015)... , July 29, 2015 /PRNewswire/ - BioAmber Inc. (NYSE: ... , the Company,s Chief Financial Officer has resigned.  The ... Chief Financial Officer who retired in December 2014, as ... for a permanent successor.     Andy Ashworth ... Laurin and ensure a smooth transition.  Andy was the ...
(Date:7/29/2015)... 29, 2015 Research ... addition of the "Global Biosimilars Market, 2015 ... The Global Biosimilars Market, 2015 - 2025, ... growing biosimilars market. With the blockbuster biologics losing ... costs, biosimilars are being viewed as viable substitutes ...
Breaking Biology Technology:Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 2Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 3BioAmber Announces Change in Chief Financial Officer 2BioAmber Announces Change in Chief Financial Officer 3Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 2Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 3
... Inc. ("Chromos" or the "Company"; TSX: CHR) today provided ... of Directors of Chromos today announced that Mr. Alistair,Duncan ... effective,immediately. He has also resigned as a Director of ... President and CEO since 1998., Mr. Roger Flowerdew, ...
... Education and Finger Health in Diabetes Management, ... 16 Pelikan,Technologies Inc., a leading developer ... Eli Lilly and Company today announced the,signing ... terms of the,co-promotion agreement, the companies will ...
... Inc.,("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that Prof. Alan,Melcher ... Hospital in Leeds,U.K. published the results of their ... Therapy. The paper is entitled "Inflammatory Tumour Cell ... The investigators showed that reovirus effectively kills ...
Cached Biology Technology:Chromos provides shareholder update 2Pelikan Technologies and Lilly Form Alliance to Promote Diabetes Education 2Pelikan Technologies and Lilly Form Alliance to Promote Diabetes Education 3Pelikan Technologies and Lilly Form Alliance to Promote Diabetes Education 4Oncolytics Biotech Inc. Announces Gene Therapy Publication on Reovirus Treatment for Melanoma 2
(Date:7/30/2015)... July 30, 2015 Cellecta, Inc., a ... function analysis and biomarker discovery, announced the release ... Library targeting all human protein coding genes. CRISPR ... out" a gene,s function. Cellecta,s new Human Whole ... screening tool so that researchers can investigate in ...
(Date:7/27/2015)... Calif. , July 27, 2015  Synaptics ... of human interface solutions, today announced that Huawei ... touchscreen solution for its stylish smartwatch. Huawei ... its proven reliability, low power and highly responsive ... wet finger. Huawei designers also required a classic ...
(Date:7/27/2015)... ANGELES , July 27, 2015   ... evidence- and experience-based clinical improvement solutions, today announced ... solution is now available on Android smartphones and ... inpatient and post-care organizations can use ZynxCarebook to ... same patient,s condition, streamline care transitions to other ...
Breaking Biology News(10 mins):CELLECTA, INC. Announces Launch of Human Whole Genome CRISPR Knockout Library 2Synaptics Touchscreen Solution Powers New Huawei Watch 2Synaptics Touchscreen Solution Powers New Huawei Watch 3Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3
... here have used a new microscopic, three-dimensional scaffolding to coax ... then to function identical to how fat cells naturally do ... fat cells, or adipocytes, in the laboratory, those cells never ... tissue. They failed to produce the genetic and biologic components ...
... have discovered a potential new drug that inhibits destructive ... all cancers. The scientists showed they could block the ... compound, called cysmethynil. , Their finding, reported in the ... Academy of Sciences, is the first step toward developing ...
... To understand the formation of the brain-clogging deposits ... diseases, Duke University chemists have figured out how ... blocks of the deposits. , Their aim is ... toxic protein called amyloid plaque. Such basic understanding, ...
Cached Biology News:Tiny scaffolding allows stem cells to become working fat cells 2Tiny scaffolding allows stem cells to become working fat cells 3Newly Discovered Compound Blocks Known Cancer-Causing Protein 2Newly Discovered Compound Blocks Known Cancer-Causing Protein 3Duke Chemists Isolating Individual Molecules Of Toxic Protein In Alzheimer's, Parkinson's Disease 2
Request Info...
... Panomer 9 oligodeoxynucleotides are ... labeled at the 5' ... Alexa Fluor dyes and ... assessing microarray spot morphology, ...
Topoisomerase I, isolated from wheat germ, is an enzyme capable of removing negative supercoils from covalently closed circular DNA (1)....
DEAD (Asp-Glu-Ala-Asp) box polypeptide 5...
Biology Products: